Arboretum Ventures

Join #HRX2024 KOL Charity Tarn, Senior Associate at Arboretum Ventures,  in Atlanta this September to push the boundaries of innovation in CV medicine. At HRX 2024, you'll gain insights into regulatory approvals, clinical trials, market adoption and the integration of novel technologies into patient care. Learn more and register today https://bit.ly/3RyZZns HRX 2024  Producers: Jennifer N. Avari Silva and Suneet Mittal HRX Production Team: Demilade Adedinsewo, Brynn Dechert-Crooks, Hamid Ghanbari, Janet K. Han, Adrian Hernandez, Rod Passman, Julie Shea, and Jacqueline Shreibati, MD, FACC. #cardiology #electrophysiology #epeeps #innovation #collaboration #transformation #digitalhealth #medtech #techquity #healthequity #AI #artificialintelligence #medicine

Arboretum Ventures has participated in a $12 million funding round for PAK BioSolutions. This investment aims to support the expanding of its commercial activities and advancing product development. Specifically, PAK BioSolutions specializes in automated continuous manufacturing systems tailored for biologics.

Today we announced another important milestone in the development of our lead investigational product candidate ATX101. The U.S. Food & Drug Administration has accepted our investigational new drug application, clearing the way for us to initiate a pivotal Phase 2B clinical trial of ATX101 for the treatment of post-surgical pain following total knee replacement surgery. This clinical trial builds on a strong foundation of clinical data from prior exploratory dose-ranging studies that demonstrated ATX101’s potential to transform the pain management paradigm. We are excited for the opportunity to further evaluate ATX101 and plan to enroll 200 trial participants at U.S. sites.     We are committed to pioneering ultra-sustained, non-opioid-based analgesic products that aid patient recovery while reducing the costs of these surgeries for patients, physicians and payors alike. Today’s milestone is another key marker on the path to a new drug application to be filed with the FDA.   More in today’s press release: https://lnkd.in/eguJ7ViK #clincaltrial #painmanagement #TKA #analgesic #bupivacaine #nonopiod #postsurgicalrecovery #drugdelivery #kneereplacement #orthopedics #orthopedicsurgery

Arboretum Ventures Managing Partner Tom Shehab, MD Joins the NVCA Board of Directors https://lnkd.in/g7-fgS4N

Avation Medical is thrilled to announce that Jill Schiaparelli, Avation Medical CEO and Co-Founder, has been named a finalist for the prestigious Entrepreneur Of The Year® 2024 East Central Award by Ernst & Young! Entrepreneur Of The Year honors many different types of business leaders for their ingenuity, courage and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to fortify it for the future. Jill's innovative vision and unwavering dedication to bring the Vivally® System to market have been driving forces behind Avation Medical's success in the medical device industry. This well-deserved recognition highlights her exceptional leadership and the impactful contributions she has made to our company's growth and innovation. Join us in congratulating Jill on this incredible achievement! Visit our website to read the full press release: https://lnkd.in/gqshPet3 #VivallySystem #IHateOAB #Overactivebladder #neuromodulation #wearableneuromodulation #closedloopneuromodulation #patientfriendly #wearabletherapeutics #futureofhealthcare #oab #medicaldevices #surgeryfree #drugfree #incontinence #bladdercontrol #pee #adultdiapers

Today, we highlighted findings from the TREAT-AHF study that were published in JACC: Heart Failure (https://bit.ly/4a4WqM5). The key finding: despite significant efforts to improve acute heart failure treatment over the past 20 years, management remains unchanged.   TREAT-AHF is a national community-based cohort study that characterizes a diverse population of 262,673 patients with HF from 2015 to 2022.   “Reprieve is committed to understanding the ADHF patient journey. The clinical evidence from the TREAT-HF study demonstrates that heart failure decongestion management has not substantially changed in 20 years. The data highlights the opportunities to improve care, but it will take a sustained partnership among hospital systems, physicians, nurses, and industry partners to solve this. Reprieve is committed to building these partnerships,” said Mark Pacyna, chief executive officer of Reprieve Cardiovascular. Reprieve is partnering with industry-leading heart failure researchers and Truveta to understand and advance acute heart failure patient outcomes. The partnership with Truveta contributed to the TREAT-AHF analysis and the publication of the manuscripts. Go here to learn more: https://bit.ly/44wkeYc

#News: Virtual Incision announces data from its Investigational Device Exemption (IDE) clinical study has been published in Diseases of Colon and Rectum. John Marks MD states, "Utilization of robotic-assisted surgery for colectomy procedures is growing and these results suggest that miniaturized robotic-assisted surgery devices can be successfully used in these complex procedures." Read the press release: https://bit.ly/3JEKLIX #MedTechNews #RoboticAssistedSurgery

Fifth Eye Inc. is pleased to announce a groundbreaking advancement in patient monitoring technology. Our latest patent enhances the capabilities of the AHI System™, providing healthcare professionals with real-time treatment feedback. Learn more about this game-changing innovation: https://lnkd.in/gez6Htpz #HealthcareInnovation #PatientMonitoring #AHISystem

AtaCor Medical Closes $28M Series C Financing to Deliver Next Generation Extravascular ICD and Pacing Options for Cardiac Rhythm Management https://lnkd.in/g3u7CSKE

Have you seen it? Yes, it's real: Our "Seeing is Believing" campaign was selected as a 2024 Manny Awards Finalist for Best Medical Device Campaign. We want to thank Med Ad News for this recognition and the incredibly talented team at Schaefer Advertising Co. for bringing so much life to this creative concept. At ViaLase, we are making the seemingly impossible possible with our visionary approach to noninvasive glaucoma treatment. See our larger-than-life campaign and learn more about our pioneering laser technology at seeingisbelieving.us #medicaltechnology #ophthalmology #mannyawards